ARIA 2016: Integrated care pathways for predictive medicine across the life cycle

  • Authors: Khaitov MR1, Namazova-Baranova LS2, Chuchalin AG3, Dayhes NA4, Ilina NI1, Kurbacheva OM1, Agache I5, Bachert C6, Bedbrook A7, Canonica GW8, Casale T9, Cruz AA10, Fokkens WJ11, Hellings PW12, Samolinski B13, Bousquet J7
  • Affiliations:
    1. Institute of Immunology
    2. Federal State Autonomous Institution «Scientific Center of Children's Health» of the Ministry of Health of the Russian Federation
    3. Russian national research medical University im.N.I.Pirogov of Ministry of health of Russia
    4. Scientific and Clinical Center of Otorhinolaryngology of FMBA of Russia
    5. Transylvaniya University Dufsov
    6. Upper Airways Research Laboratory, Ghent University Hospital
    7. MACVIA-LR, Contre les MAladies Chroniques pour un VIeillissement Actif en Languedoc-Roussillon, European Innovation Partnership on Active and Healthy Ageing Reference Site
    8. Allergy and Respiratory Diseases Clinic, DIMI, University of Genoa
    9. Division of Allergy and Immunology, University of South Florida
    10. ProAR - Nucleo de Excelencia em Asma, Federal University of Bahia
    11. Department of Otorhinolaryngology, Academic Medical Centre, Amsterdam
    12. Department of Microbiology and Immunology, Laboratory of Clinical Immunology, KU Leuven
    13. Department of Prevention of Environmental Hazards and Allergology, Medical University of Warsaw
  • Issue: Vol 14, No 3 (2017)
  • Pages: 46-54
  • Section: Articles
  • Submitted: 10.03.2020
  • Published: 15.12.2017
  • URL: https://rusalljournal.ru/raj/article/view/312
  • DOI: https://doi.org/10.36691/RJA312
  • ID: 312


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The Allergic Rhinitis and its Impact on Asthma (ARIA) initiative commenced during a World Health Organization (WHO) workshop in 1999. The initial goals were to propose a new allergic rhinitis classification, to promote the concept of multi-morbidity in asthma and rhinitis and to develop guidelines with all stakeholders for global use in all countries and populations. ARIA - disseminated and implemented in over 70 countries globally - is now focusing on the implementation of emerging technologies for individualized and predictive medicine. MASK [MACVIA (Contre les MAladies Chroniques pour un Vieillissement Actif) - ARIA Sentinel NetworK] uses mobile technology to develop care pathways in order to enable the management of rhinitis and asthma by a multi-disciplinary group or by patients themselves. An App (Android and iOS) is available in 20 countries and 15 languages. It uses a visual analogue scale to assess symptom control and work productivity as well as a clinical decision support system. It is associated with an inter-operable tablet for physicians and other health care professionals. The scaling up strategy uses the recommendations of the European Innovation Partnership on Active and Healthy Ageing. The aim of the novel ARIA approach is to provide an active and healthy life to rhinitis sufferers, whatever their age, sex or socio-economic status, in order to reduce health and social inequalities incurred by the disease.

Full Text

Restricted Access

About the authors

M R Khaitov

Institute of Immunology

Email: mr.khaitov@nrcii.ru

L S Namazova-Baranova

Federal State Autonomous Institution «Scientific Center of Children's Health» of the Ministry of Health of the Russian Federation

A G Chuchalin

Russian national research medical University im.N.I.Pirogov of Ministry of health of Russia

N A Dayhes

Scientific and Clinical Center of Otorhinolaryngology of FMBA of Russia

N I Ilina

Institute of Immunology

O M Kurbacheva

Institute of Immunology

I Agache

Transylvaniya University Dufsov

C Bachert

Upper Airways Research Laboratory, Ghent University Hospital

A Bedbrook

MACVIA-LR, Contre les MAladies Chroniques pour un VIeillissement Actif en Languedoc-Roussillon, European Innovation Partnership on Active and Healthy Ageing Reference Site

G W Canonica

Allergy and Respiratory Diseases Clinic, DIMI, University of Genoa

T Casale

Division of Allergy and Immunology, University of South Florida

A A Cruz

ProAR - Nucleo de Excelencia em Asma, Federal University of Bahia

W J Fokkens

Department of Otorhinolaryngology, Academic Medical Centre, Amsterdam

P W Hellings

Department of Microbiology and Immunology, Laboratory of Clinical Immunology, KU Leuven

B Samolinski

Department of Prevention of Environmental Hazards and Allergology, Medical University of Warsaw

J Bousquet

MACVIA-LR, Contre les MAladies Chroniques pour un VIeillissement Actif en Languedoc-Roussillon, European Innovation Partnership on Active and Healthy Ageing Reference Site

References

  1. Shekelle P.G., Woolf S.H., Eccles M., Grimshaw J. Clinical guidelines: developing guidelines. Bmj. 1999, v. 318, p. 593-596.
  2. Bousquet J., van Cauwenberge P., Khaltaev N. Allergic rhinitis and its impact on asthma. J. Allergy Clin. Immunol. 2001, v. 108, p. 147-334.
  3. Bousquet J., Khaltaev N., Cruz A.A. et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA2LEN and AllerGen). Allergy. 2008, v. 63, p. 8-160.
  4. Brozek J.L., Bousquet J., Baena-Cagnani C.E. et al. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 revision. J. Allergy Clin. Immunol. 2010, v. 126, p. 466-476.
  5. Padjas A., Kehar R., Aleem S. et al. Methodological rigor and reporting of clinical practice guidelines in patients with allergic rhinitis: QuGAR study. J. Allergy Clin. Immunol. 2014, v. 133, p. 777-783.
  6. Bousquet J., Schunemann H.J., Samolinski B. et al. Allergic Rhinitis and its Impact on Asthma (ARIA): achievements in 10 years and future needs. J. Allergy Clin. Immunol. 2012, v. 130, p. 1049-1062.
  7. Bousquet J., Addis A., Adcock I. et al. Integrated care pathways for airway diseases (AIRWAYS-ICPs). Eur. Respir. J. 2014, v. 44, p. 304-23.
  8. Bousquet J., Hellings P.W., Agache I. et al. ARIA 2016: Care pathways implementing emerging technologies for predictive medicine in rhinitis and asthma across the life cycle. Clin. Transl. Allergy. 2016, v. 6, p. 47.
  9. Bousquet J., Michel J., Standberg T. et al. The European Innovation Partnership on Active and Healthy Ageing: the European Geriatric Medicine introduces the EIP on AHA Column. Eur. Geriatr. Med. 2014, v. 5, p. 361-362.
  10. Bousquet J., Anto J.M., Berkouk K. et al. Developmental determinants in non-communicable chronic diseases and ageing. Thorax. 2015, v. 70, p. 595-597.
  11. Bousquet J., Barbara C., Bateman E. et al. AIRWAYS-ICPs (European Innovation Partnership on Active and Healthy Ageing) from concept to implementation. Eur. Respir. J. 2016, v. 47, p. 1028-1033.
  12. Bousquet J., Farrell J., Crooks G. et al. Scaling up strategies of the chronic respiratory disease programme of the European Innovation Partnership on Active and Healthy Ageing (Action Plan B3: Area 5). Clin. Transl. Allergy. 2016, v. 6, p. 29.
  13. Bousquet J., Bewick M., Cano A. et al. Building Bridges for Innovation in Ageing: Synergies between Action Groups of the EIP on AHA. J. Nutr. Health Aging. 2017, v. 21, p. 92-104.
  14. Kuehl B.L., Abdulnour S., O’Dell M., Kyle T.K. Understanding the role of the healthcare professional in patient self-management of allergic rhinitis. SAGE Open Med. 2015, v. 19. doi: 10.1177/2050312115595822.
  15. ARIA in the pharmacy: management of allergic rhinitis symptoms in the pharmacy. Allergic rhinitis and its impact on asthma. Allergy. 2004, v. 59, p. 373-387.
  16. Canonica G.W., Triggiani M., Senna G. 360 degree perspective on allergic rhinitis management in Italy: a survey of GPs, pharmacists and patients. Clin. Mol. Allergy. 2015, v. 13, p. 25.
  17. Meltzer E.O., Farrar J.R., Sennett C. Findings from an Online Survey Assessing the Burden and Management of Seasonal Allergic Rhinoconjunctivitis in US Patients. J. Allergy Clin. Immunol. Pract. 2016.
  18. Bousquet J., Annesi-Maesano I., Carat F. et al. Characteristics of intermittent and persistent allergic rhinitis: DREAMS study group. Clin. Exp. Allergy. 2005, v. 35, p. 728-732.
  19. Bousquet P.J., Devillier P., Tadmouri A. et al. Clinical Relevance of Cluster Analysis in Phenotyping Allergic Rhinitis in a Real-Life Study. Int. Arch. Allergy Immunol. 2015, v. 166, p. 231-240.
  20. Del Cuvillo A., Montoro J., Bartra J. et al. Validation of ARIA duration and severity classifications in Spanish allergic rhinitis patients - The ADRIAL cohort study. Rhinology. 2010, v. 48, p. 201-205.
  21. Calderon M.A., Demoly P., Casale T et al. Allergy immunotherapy across the life cycle to promote active and healthy ageing: from research to policies: An AIRWAYS Integrated Care Pathways (ICPs) programme item (Action Plan B3 of the European Innovation Partnership on active and healthy ageing) and the Global Alliance against Chronic Respiratory Diseases (GARD), a World Health Organization GARD research demonstration project. Clin. Transl. Allergy. 2016, v. 6, p. 41.
  22. Cruz A.A., Popov T., Pawankar R. et al. Common characteristics of upper and lower airways in rhinitis and asthma: ARIA update, in collaboration with GA2LEN. Allergy. 2007, v. 62, p. 1-41.
  23. Bousquet P.J., Devillier P., Tadmouri A. et al. Clinical relevance of cluster analysis in phenotyping allergic rhinitis in a real-life study. Int. Arch. Allergy Immunol. 2015, v. 166, p. 231-240.
  24. Meltzer E.O., Wallace D., Dykewicz M., Shneyer L. Minimal Clinically Important Difference (MCID) in Allergic Rhinitis: Agency for Healthcare Research and Quality or Anchor-Based Thresholds? J. Allergy Clin. Immunol. Pract. 2016, v. 4, p. 682-688.
  25. Bousquet J., Schunemann H.J., Fonseca J. et al. MACVIA-ARIA Sentinel NetworK for allergic rhinitis (MASK-rhinitis): the new generation guideline implementation. Allergy. 2015, v. 70, p. 1372-1392.
  26. Bourret R., Bousquet J. et al. MASK rhinitis, a single tool for integrated care pathways in allergic rhinitis. World Hosp. Health Serv. 2015, v. 51, p. 36-39.
  27. Bousquet J., Schunemann H.J., Hellings P.W. et al. MACVIA clinical decision algorithm in adolescents and adults with allergic rhinitis. J. Allergy Clin. Immunol. 2016, v. 138, p. 367-374.
  28. Bousquet J., Caimmi D., Bedbrook A. et al. Pilot study of mobile phone technology in allergic rhinitis in European countries. The MASK-rhinitis study Allergy. 2017: in press.
  29. Konig H.H., Bernert S., Angermeyer M.C. et al. Comparison of population health status in six european countries: results of a representative survey using the EQ-5D questionnaire. Med. Care. 2009, v. 47, p. 255-261.
  30. Blanc P.D., Trupin L., Eisner M. et al. The work impact of asthma and rhinitis: findings from a population-based survey. J. Clin. Epidemiol. 2001, v. 54, p. 610-618.
  31. Bousquet J., Bachert C., Canonica G.W. et al. Unmet needs in severe chronic upper airway disease (SCUAD). J. Allergy Clin. Immunol. 2009, v. 124, p. 428-433.
  32. Bousquet J., Anto J., Sunyer J. et al. Pooling birth cohorts in allergy and asthma: European Union-funded initiatives - a MeDALL, CHICOS, ENRIECO, and GA(2)LENjoint paper. Int. Arch. Allergy Immunol. 2013, v. 161, p. 1-10.
  33. Westman M., Lupinek C., Bousquet J. et al. Early childhood IgE reactivity to pathogenesis-related class 10 proteins predicts allergic rhinitis in adolescence. J. Allergy Clin. Immunol. 2015, v. 135, p. 1199-1206.
  34. Bousquet J., Anto J.M., Akdis M. et al. Paving the way of systems biology and precision medicine in allergic diseases: The MeDALL success story. Allergy. 2016, v. 71, p. 1513-1525.
  35. Burte E., Bousquet J., Varraso R. et al. Characterization of Rhinitis According to the Asthma Status in Adults Using an Unsupervised Approach in the EGEA Study. PLoS One. 2015, v. 10, p. e0136191.
  36. Siroux V., Lupinek C., Resch Y. et al. Specific IgE and IgG measured by the MeDALL allergen-chip depend on allergen and route of exposure: The EGEA study. J. Allergy Clin. Immunol. 2017, v. 139, p. 643-654.
  37. Just J., Elegbede C.F., Deschildre A. et al. Three peanut allergic/sensitized phenotypes with gender difference. Clin. Exp. Allergy. 2016, v. 46, p. 1596-1604.
  38. Zoratti E.M., Krouse R.Z., Babineau D.C. et al. Asthma phenotypes in inner-city children. J. Allergy Clin. Immunol. 2016, v. 138, p. 1016-1029.
  39. Bresciani M., Paradis L., Des Roches A. et al. Rhinosinusitis in severe asthma. J. Allergy Clin. Immunol. 2001, v. 107, p. 73-80.
  40. Ten Brinke A., Grootendorst D.C., Schmidt J.T. et al. Chronic sinusitis in severe asthma is related to sputum eosinophilia. J. Allergy Clin. Immunol. 2002, v. 109, p. 621-626.
  41. Козулина И.Е., Курбачева О.М., Ильина Н.И. Аллергия сегодня. Анализ новых эпидемических данных. Рос. Аллергол. Журн. 2014, № 3, с. 3-11.
  42. Федеральные клинические рекомендации по диагностике и лечению аллергического ринита. В кн.: Аллергология. Федеральные клинические рекомендации. Под ред. Р.М. Хаитова, Н.И. Ильиной. «Фармарус Принт Медиа». М., 2014, с. 20-34.
  43. Аллерген-специфическая иммунотерапия. Федеральные клинические рекомендации. В кн.: Аллергология. Федеральные клинические рекомендации. Под ред. Р.М. Хаитова, Н.И. Ильиной. «Фармарус Принт Медиа». М., 2014, с. 106-119.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright © Pharmarus Print Media, 2017